Previous Close | 3.4000 |
Open | 3.4300 |
Bid | 3.2800 x 900 |
Ask | 3.3800 x 1000 |
Day's Range | 3.1700 - 3.4300 |
52 Week Range | 1.7700 - 7.4000 |
Volume | |
Avg. Volume | 295,937 |
Market Cap | 66.912M |
Beta (5Y Monthly) | 2.16 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.2270 |
Earnings Date | Mar 29, 2023 - Apr 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for SLS
Event will Feature Presentation from Hematology Oncology Expert Omer Jamy, MD, Phase 3 REGAL Study Principal Investigator at the University of Alabama Participating Site Webcast to be held on Tuesday, January 31, 2023, at 8:30 a.m. EST NEW YORK, Jan. 19, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, will hos
Andrew Elnatan Brings Nearly Three Decades of Global Regulatory Experience with Successful Breakthrough Therapy Designation and Global Drug ApprovalsNEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the appointment of Andrew Elnatan as Vice President, Head of Regulatory Affairs
SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced results from its ongoing dose-escalating Phase 1 study of GFH009 in patients with relapsed and/or refractory (r/r) hematologic malignancies. One patient treated with GFH009 in the 30 mg once-per-week cohort achieved a confirmed complete response (CR), which is the first CR reported in acute myeloid leukemia (AML) with any CDK9 inhibitor monotherapy. No minimal residual disease (MRD) was detected in this CR patient, and full neutrophil, plate